In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Cardiff Oncology, with a price target of $10.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Robert Burns has given his Buy rating due to a combination of factors, chiefly the promising clinical performance of onvansertib in the CRDF-004 study in first-line RAS-mutated metastatic colorectal cancer. The onvansertib combination showed a meaningfully higher confirmed objective response rate and a notable reduction in the risk of progression or death versus standard-of-care, supporting the company’s plans to move into a randomized Phase 3 trial and positioning 1H26 as an important catalyst window.
Burns also highlights that Cardiff’s 2025 financial results tracked close to expectations, with controlled R&D and SG&A spending, an improved projected 2026 net loss, and a cash balance he believes can fund operations into early 2027. Using a DCF-based analysis with conservative assumptions and a modest probability of launch for onvansertib, he derives an equity value that supports a $10, 12‑month price target, while acknowledging clinical, regulatory, commercial, and dilution risks that investors should monitor.